GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » EV-to-FCF

Purple Biotech (XTAE:PPBT) EV-to-FCF : 0.04 (As of May. 01, 2024)


View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Purple Biotech's Enterprise Value is ₪-3.01 Mil. Purple Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-74.52 Mil. Therefore, Purple Biotech's EV-to-FCF for today is 0.04.

The historical rank and industry rank for Purple Biotech's EV-to-FCF or its related term are showing as below:

XTAE:PPBT' s EV-to-FCF Range Over the Past 10 Years
Min: -2.45   Med: -0.46   Max: 0.35
Current: 0.02

During the past 11 years, the highest EV-to-FCF of Purple Biotech was 0.35. The lowest was -2.45. And the median was -0.46.

XTAE:PPBT's EV-to-FCF is ranked better than
96.18% of 393 companies
in the Biotechnology industry
Industry Median: 4.47 vs XTAE:PPBT: 0.02

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Purple Biotech's stock price is ₪0.21. Purple Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.339. Therefore, Purple Biotech's PE Ratio for today is At Loss.


Purple Biotech EV-to-FCF Historical Data

The historical data trend for Purple Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech EV-to-FCF Chart

Purple Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.35 -0.08 -0.69 0.36 -0.33

Purple Biotech Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 -0.67 -0.69 -0.46 -0.33

Competitive Comparison of Purple Biotech's EV-to-FCF

For the Biotechnology subindustry, Purple Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Purple Biotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Purple Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Purple Biotech's EV-to-FCF falls into.



Purple Biotech EV-to-FCF Calculation

Purple Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-3.005/-74.523
=0.04

Purple Biotech's current Enterprise Value is ₪-3.01 Mil.
Purple Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-74.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Purple Biotech  (XTAE:PPBT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Purple Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.21/-0.339
=At Loss

Purple Biotech's share price for today is ₪0.21.
Purple Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-0.339.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Purple Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Purple Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Purple Biotech (XTAE:PPBT) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.